8-K: Tevogen Bio Establishes $50 Million At-The-Market Equity Offering Program

Tevogen Bio Holdings Inc. has entered into a sales agreement with A.G.P./Alliance Global Partners to sell up to $50 million of its common stock through an at-the-market equity offering.

Summary

• Tevogen Bio Holdings Inc. (the "Company") entered into a Sales Agreement (the "Sales Agreement") with A.G.P./Alliance Global Partners (the "Agent") on July 3, 2025.
• The Sales Agreement allows the Company to issue and sell from time to time up to $50,000,000 of its common stock through the Agent as its sales agent.
• Sales will be conducted as an "at-the-market" equity offering, as defined in Rule 415 under the Securities Act of 1933, utilizing the Company's effective shelf registration statement on Form S-3 (File No. 333-288218), which was filed on June 20, 2025, and declared effective on June 26, 2025.
• The Company will provide placement notices to the Agent, specifying parameters such as the number of shares to be sold, the time period for sales, any daily sales limitations, and any minimum price below which sales may not be made.
• The Agent will use commercially reasonable efforts to sell the common stock based on the Company's instructions.
• The Company is not obligated to make any sales under the Sales Agreement and retains the right to terminate the agreement at any time upon written notice.
• The Company will pay the Agent a commission of 3.00% on the gross proceeds from each sale of common stock.
• The Company will reimburse the Sales Agent for reasonable and documented out-of-pocket costs and expenses, including legal fees, up to $40,000 upon execution, an additional aggregate of $5,000 per calendar quarter (not exceeding $20,000 per fiscal year), and up to $10,000 for each program refresh.

Sentiment

Score: 6

Explanation: The establishment of an ATM offering provides financial flexibility and access to capital, which is generally positive for a company, especially in the biotech sector. However, it also implies a need for funds and carries the potential for shareholder dilution, leading to a moderately positive sentiment rather than strongly positive.

Positives

• Provides Tevogen Bio with a flexible and efficient mechanism to raise capital as needed, adapting to market conditions.
• Allows the Company to access public markets for funding without the need for traditional underwritten offerings, potentially reducing costs and time.
• The "at-the-market" structure offers discretion over the timing and pricing of share sales, which can help minimize market impact.
• The Company is not obligated to make any sales, providing financial optionality and control over the capital raising process.

Negatives

• Potential for dilution of existing shareholders as new common stock shares are issued under the program.
• Sales under the program could put downward pressure on the stock price, particularly if large volumes are sold over short periods.
• The 3.00% commission paid to the agent reduces the net proceeds received by the Company from each sale.
• The Company incurs certain expenses related to the program, including legal and filing fees, regardless of whether sales are consummated.

Risks

• Market Conditions: The ability to sell shares and the price at which they can be sold are subject to prevailing market conditions and demand for the Company's common stock.
• Dilution: Future sales of common stock under the agreement will dilute the ownership interest of existing shareholders.
• Regulatory Compliance: The Company must maintain compliance with SEC and Nasdaq rules, including timely filings, accurate disclosures, and listing requirements, to continue the program.
• Material Adverse Change: The Sales Agent can terminate the agreement if a material adverse change occurs that, in its reasonable judgment, materially impairs its ability to sell the Placement Shares.
• Suspension of Sales: Sales can be suspended by either party, or if the Company possesses material non-public information, which could limit capital raising flexibility.
• Financial Reporting Controls: The Company must maintain effective internal control over financial reporting, and any material weakness could impact its ability to utilize the ATM program.
• Intellectual Property Infringement: Potential claims of infringement or challenges to the Company's intellectual property rights could result in a Material Adverse Change.
• Compliance with Laws: Non-compliance with applicable laws (e.g., FDA, environmental, tax, anti-corruption, money laundering) could lead to material adverse changes.
• Delisting Risk: Suspension or delisting of the Common Stock from Nasdaq would permit the Sales Agent to terminate the agreement.
• Integration of Prior Offerings: The Company must ensure that the offer and sale of Placement Shares are not integrated with prior offerings in a way that would require additional registration under the Securities Act.
• Regulatory Matters: The Company's clinical trials and nonclinical studies must be conducted in material compliance with all applicable laws and regulations, and any issues could impact the Company's prospects and ability to raise capital.

Future Outlook

The document outlines a mechanism for future capital raises, indicating the Company's intent to maintain financial flexibility and potentially fund ongoing operations or strategic initiatives. It does not provide specific financial guidance or projections regarding future performance.

Management Comments

• Tevogen Bio Holdings Inc. (the Company) entered into a Sales Agreement (the Sales Agreement) with A.G.P./Alliance Global Partners (the Agent), pursuant to which the Company may issue and sell from time to time up to $50,000,000 of shares of its common stock...
• The Company is not obligated to make any sales of Common Stock under the Sales Agreement and may terminate the Sales Agreement at any time upon written notice.

Industry Context

At-the-market (ATM) equity offerings are a common financing tool, particularly for biotechnology and pharmaceutical companies, which often require significant capital for research, development, and clinical trials. This mechanism provides a flexible and cost-effective way to raise funds incrementally, adapting to market conditions and specific funding needs, rather than relying on large, discrete public offerings. It allows companies to manage dilution more strategically and access capital efficiently to support long-term growth and innovation in a capital-intensive industry.

Comparison to Industry Standards

• The establishment of an At-The-Market (ATM) equity offering program is a standard financing strategy for publicly traded companies, especially those in growth-oriented or capital-intensive sectors like biotechnology.
• The maximum offering amount of $50 million is a typical size for such programs, providing a reasonable funding runway without immediately saturating the market.
• The 3.00% commission rate to the sales agent is within the customary range for ATM offerings, which generally fall between 1% and 5% of gross proceeds, reflecting the agent's role in facilitating sales on an "as-needed" basis.
• The use of a shelf registration statement on Form S-3 is standard practice for companies that meet the eligibility requirements, allowing for efficient and flexible access to capital markets over a three-year period.

Corporate Governance

Related Party Transactions

• The Company's loan agreement, dated June 6, 2024, with The Patel Family, LLP, is mentioned as an exception to restrictions on other sales of common stock or convertible securities during the pendency of a Placement Notice, indicating a pre-existing related party financial arrangement.

Stakeholder Impact

• Shareholders: Potential for dilution of existing shareholdings due to the issuance of new common stock, which could impact per-share metrics.
• Company: Enhanced financial flexibility and access to capital for ongoing operations, research, and development, supporting strategic objectives.
• Agent (A.G.P./Alliance Global Partners): Benefits from a 3.00% commission on gross proceeds from sales, generating revenue for its services.
• Creditors: The capital raise could improve the Company's liquidity and financial position, potentially reducing credit risk.

Next Steps

• The Company may issue Placement Notices to the Agent to initiate sales of common stock under the program.
• The Agent will use commercially reasonable efforts to sell shares based on the Company's instructions and market conditions.
• The Company will continue to file required reports and amendments with the SEC and Nasdaq to maintain compliance and program effectiveness.
• The Company will make generally available an earnings statement covering a 12-month period, as required by Section 11(a) and Rule 158 of the Securities Act, within 15 months after the end of the current fiscal quarter.

Key Dates

Keywords

Tevogen Bio, TVGN, At-The-Market, ATM offering, equity offering, common stock, capital raise, SEC filing, Form 8-K, A.G.P./Alliance Global Partners, dilution, financial flexibility, Nasdaq